Syncom Formulation (India) Ltd
Wed 30/04/2025,15:57:22 | NSE : SYNCOMF
Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
Open
₹ 16.81
Previous Close
₹ 16.81
Volume
2213456
Mkt Cap ( Rs. Cr)
₹1534.08
High
₹ 16.89
Low
₹ 16.25
52 Week High
₹ 27.90
52 Week Low
₹ 10.95
Book Value Per Share
₹ 3.34
Dividend Yield
0.00
Face Value
₹ 1.00
What’s Your Call?
Collective community sentiment on Syncom Formulation (India) Ltd
Your Vote -
Buy
76.85%
Hold
17.28%
Sell
5.87%
76.85%
1823 users have voted
Market Depth
How many stocks are available to buy or sell and at what prices.
Buy Order Quantity
100%
Sell Order Quantity
0%
Bid Price
Qty
16.32
109
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
109
Bid Price
Qty
0.00
0
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
0
Option Chain
Analyzes market sentiment, predicts Syncom Formulation (India) Ltd' movement.
NO_RECORD_FOUND
News
Media spotlight triggers stock stock attention, sentiment.
-
Syncom Formul. - Certificate under SEBI (Depositories and Participants) Regulations, 2018
-
Syncom Formul. - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
-
Syncom Formul. has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2025
-
Syncom Formul. - General Updates
-
Syncom Formul. - Announcement Under Regulation 30
-
Syncom Formul. - Trading Window-XBRL
-
Syncom Formul. - Trading Window
-
Syncom Formul. - Updates
-
Syncom Formul. - Disclosure of material issue
-
Syncom Formul. - Disclosure under Regulation 30A of LODR
-
Syncom Formul. - Copy of Newspaper Publication
-
Syncom Formul. - Integrated Filing- Financial
-
Syncom Formul. - Financial Result Updates
-
Syncom Formul. Q3 net profit jumps 99.22% at Rs 12.79 cr
-
Syncom Formul. - Integrated Filing (Financial)
-
Syncom Formul. - Regulation 33(3) Of SEBI (LODR) Regulations, 2015 - Submission Of Standalone & Consolidated Unaudited Financ
-
Syncom Formul. - Board Meeting Intimation
-
Syncom Formul. - Compliances-Reg. 50 (1) - Prior intimation about Board meeting under Regulation 50(1)
Key fundamentals
Evaluate the intrinsic value of Syncom Formulation (India) Ltd stock
Name | March-24 | March-23 | March-22 | March-21 | March-20 |
---|---|---|---|---|---|
Assets | 358.1021 | 339.1962 | 280.0124 | 249.674 | 147.7977 |
Liabilities | 358.1021 | 339.1962 | 280.0124 | 249.674 | 147.7977 |
Equity | 94 | 94 | 86.2453 | 78.9952 | 78.0652 |
Gross Profit | 27.8543 | 19.6132 | 19.4629 | 37.8388 | 16.64 |
Net Profit | 23.6232 | 20.0707 | 19.7904 | 29.1719 | 14.2534 |
Cash From Operating Activities | -5.9376 | 10.4962 | 16.329 | -150.1536 | -0.5056 |
NPM(%) | 9.14 | 8.93 | 9 | 11.91 | 6.93 |
Revenue | 258.3596 | 224.6439 | 219.6632 | 244.805 | 205.511 |
Expenses | 230.5053 | 205.0307 | 200.2003 | 206.9661 | 188.871 |
ROE(%) | 7.53 | 6.4 | 6.31 | 9.3 | 4.54 |
Corporate Action
XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
---|
Peers
Other companies within the same industry or sector that are comparable to Syncom Formulation (India) Ltd
Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
---|---|---|---|---|---|---|
Albert David Ltd | 825.75 | -1.80 | 11.65 | 9.31 | 1321.50 | 1.39 |
Lotus Eye Hospital and Institute Ltd | 81.22 | -0.17 | 338.42 | 33.94 | 14.01 | 0.62 |
Vaishali Pharma Ltd | 13.47 | -1.82 | 449.00 | 17.49 | 2.76 | 0.00 |
Astec Lifesciences Ltd | 685.90 | -1.03 | 0.00 | 32.00 | -687.11 | 0.00 |
Company Info
Syncom Formulations (India) Limited - a renowned name in the Indian Pharmaceutical Industry represents SYNergistic COMbination for health. -Syncom possesses the manufacturing strength in its own manufacturing set-up at Pithampur (30kms away from Indore, the commercial capital of Madhya Pradesh, India). Established in the year 1995, Syncom's state of art WHO-GMP and ISO 9001-2015 certified plant is geared up with latest production machineries and maintains high quality standards. Currently pharmaceutical formulation products SYNCOM manufactures and markets more than 500 products in various dosage forms like Tablets, Capsules, Liquids Orals, Liquid Vials & Ampoule Injections & Dry powder injections, Ophthalmic preparations, Dry Syrups and suspensions , Ointments, Creams, Gel , ORS & Jelly 1988 -Syncom Formulation (India) Ltd. was established. 2005 -Company had allotted 2.65lakh fully paid-up equity shares of Rs 10 each at a premium of Rs 80 per share on the preferential basis. 2006 -Board of directors of the company had considered issue of 2.95 equity shares aggregating to Rs 1.59 crore on preferential basis. -The comapny approved an Rs 7.1 crore plan to install two wind mills of 0.60 MW each at Sangli in Maharashtra. 2008 -Board of directors of the company had approved amendment in the Articles of Association for insertion of clauses relating to authorizing the board for issuance of warrants convertible into equity shares of the company. -On 25th March 2008, board of directors of the company had transacted the allotment of 3.1 lakh equity shares of Rs 10 each by way of preferential allotment at a premium of Rs 36per equity share to Shri. Kedarmal Bankda, promoter of the company. -On the same date board of directors of the company had transacted the allotment of 3.25 lakh warrants of Rs 46 each. 2009 -Syncom Formulations India has recommended the dividend @ Rs. 0.50 (5%) on equity shares of Rs. 10/- each -Syncom Formulation (India) Ltd Issues Rights in the Ratio of 1:2 2011 -Mrs. Shikha Sethi, has been appointed as the Company secretary of the Company 2012 -Company has incorporated a Wholly Owned Subsidiary Company in the name of "TRADE ZONE FZE" in the United Arab Emirates -Shri. Praveen Jindal has been appointed as an Independent Director of the company. 2013 -The Company in the proportion of 5 (Five) Equity Shares of Rs. 1 (Rs. One) for every 2 (Two) Equity Shares of Rs. 1 (Rs. One) held by them on the record date as may be decided by the Board with the consultation of the Stock Exchange. -The Company has recommend a dividend Rs. 0.60 (Sixty paise) (6%) per equity share of Rs. 10/- each for the year 2012-13, -Syncom Formulation (India) has announces bonus in the ratio of 5:2 -Syncom Formulation (India) has splits its face value from Rs 10/- to 1/- 2014 -The Company has recommend a dividend of Rs. 0.02 (Two paise) (2%) per equity share of Re. 1/- each for the year 2013-14 -The Company has appointed Smt. Rinki Bankda in the category of Women Director as an Additional Director of the Company w.e.f. August 13, 2014. 2022 -Syncom Formulations (India) Limited has awarded 'PRODUCT EXCELLENCE 2022' under the category of 'Pharma (Medium)'organized.
Syncom Formulations (India) Limited - a renowned name in the Indian Pharmaceutical Industry represents SYNergistic COMbination for health. -Syncom possesses the manufacturing strength in its own manufacturing set-up at Pithampur (30kms away from Indore, the commercial capital of Madhya Pradesh, India). Established in the year 1995, Syncom's state of art WHO-GMP and ISO 9001-2015 certified plant is geared up with latest production machineries and maintains high quality standards. Currently pharmaceutical formulation products SYNCOM manufactures and markets more than 500 products in various dosage forms like Tablets, Capsules, Liquids Orals, Liquid Vials & Ampoule Injections & Dry powder injections, Ophthalmic preparations, Dry Syrups and suspensions , Ointments, Creams, Gel , ORS & Jelly 1988 -Syncom Formulation (India) Ltd. was established. 2005 -Company had allotted 2.65lakh fully paid-up equity shares of Rs 10 each at a premium of Rs 80 per share on the preferential basis. 2006 -Board of directors of the company had considered issue of 2.95 equity shares aggregating to Rs 1.59 crore on preferential basis. -The comapny approved an Rs 7.1 crore plan to install two wind mills of 0.60 MW each at Sangli in Maharashtra. 2008 -Board of directors of the company had approved amendment in the Articles of Association for insertion of clauses relating to authorizing the board for issuance of warrants convertible into equity shares of the company. -On 25th March 2008, board of directors of the company had transacted the allotment of 3.1 lakh equity shares of Rs 10 each by way of preferential allotment at a premium of Rs 36per equity share to Shri. Kedarmal Bankda, promoter of the company. -On the same date board of directors of the company had transacted the allotment of 3.25 lakh warrants of Rs 46 each. 2009 -Syncom Formulations India has recommended the dividend @ Rs. 0.50 (5%) on equity shares of Rs. 10/- each -Syncom Formulation (India) Ltd Issues Rights in the Ratio of 1:2 2011 -Mrs. Shikha Sethi, has been appointed as the Company secretary of the Company 2012 -Company has incorporated a Wholly Owned Subsidiary Company in the name of "TRADE ZONE FZE" in the United Arab Emirates -Shri. Praveen Jindal has been appointed as an Independent Director of the company. 2013 -The Company in the proportion of 5 (Five) Equity Shares of Rs. 1 (Rs. One) for every 2 (Two) Equity Shares of Rs. 1 (Rs. One) held by them on the record date as may be decided by the Board with the consultation of the Stock Exchange. -The Company has recommend a dividend Rs. 0.60 (Sixty paise) (6%) per equity share of Rs. 10/- each for the year 2012-13, -Syncom Formulation (India) has announces bonus in the ratio of 5:2 -Syncom Formulation (India) has splits its face value from Rs 10/- to 1/- 2014 -The Company has recommend a dividend of Rs. 0.02 (Two paise) (2%) per equity share of Re. 1/- each for the year 2013-14 -The Company has appointed Smt. Rinki Bankda in the category of Women Director as an Additional Director of the Company w.e.f. August 13, 2014. 2022 -Syncom Formulations (India) Limited has awarded 'PRODUCT EXCELLENCE 2022' under the category of 'Pharma (Medium)'organized.
Read More
Parent Organisation
Syncom Formulation (India) Ltd.
Founded
21/06/1988
Managing Director
Mr.Vijay Shankarlal Bankda
NSE Symbol
SYNCOMFEQ
FAQ
The current price of Syncom Formulation (India) Ltd is ₹ 16.32.
The 52-week high for Syncom Formulation (India) Ltd is ₹ 16.89 and the 52-week low is ₹ 16.25.
The market capitalization of Syncom Formulation (India) Ltd is currently ₹ 1534.08. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.
To buy Syncom Formulation (India) Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in Syncom Formulation (India) Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Syncom Formulation (India) Ltd shares.
The CEO of Syncom Formulation (India) Ltd is Mr.Vijay Shankarlal Bankda, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.